- Editas Medicine (NASDAQ:EDIT +4.9%) Q1 results: Revenues: $0.8M; R&D Expense: $9.8M (+197.0%); SG&A: $8.9M (+368.4%); Operating Loss: ($17.8M) (-242.3%); Net Loss: ($17.7M) (-234.0%); Loss Per Share: ($0.80) (+70.9%); Quick Assets: $229.2M (+60.1%).
- No guidance given.
Editas Medicine reports Q1 results
Recommended For You
About EDIT Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| EDIT | - | - |
| Editas Medicine, Inc. | ||